3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Gastrointestinal
1
CNS
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neurofibromatosis 2
1
Neoplasms
1
Neoplasm Metastasis
1
Colonic Neoplasms
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Temozolomide
163
Radiosurgery
129
Radiotherapy
107
Bevacizumab
98
Magnetic Resonance Spectroscopy
75
Carboplatin
48
Surgical Procedures, Operative
35
pembrolizumab
34
Radiation
34
Etoposide
34
Nivolumab
33
Irinotecan
33
Cyclophosphamide
33
Erlotinib Hydrochloride
31
Carmustine
28
Lomustine
26
Trastuzumab
25
Cisplatin
25
Ipilimumab
24
Filgrastim
23
Mental Status and Dementia Tests
21
Magnetic Resonance Imaging
21
Aminolevulinic Acid
21
Vincristine
20
Surveys and Questionnaires
19
Capecitabine
19
Topotecan
18
Specimen Handling
18
Pemetrexed
18
Radiotherapy, Intensity-Modulated
16
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Brain Neoplasms
×
Doxycycline
×
CNS
×
Clear all
NCT02201381
2022-07-18
METRICS
Health Clinics Limited
Phase 3
Withdrawn